Moxifloxacin is used to treat respiratory infections including: Acute sinusitis caused by: H. influenzae, M. catarrhalis, S. pneumoniae. Acute exacerbations of chronic bronchitis caused by: H. influenzae, H. parainfluenzae, K. pneumoniae, M. catarrhalis, S. aureus, S. pneumoniae.
Community-acquired pneumonia of Mild to Moderate Severity caused by: C. pneumoniae, H. influenzae, M. catarrhalis, M. pneumoniae, S. pneumoniae.
Community-acquired pneumonia (CAP), including CAP caused by multi-drug resistant Streptococcus pneumoniae.
Moxifloxacin is used to treat complicated skin and skin structure infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae and Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.
Moxifloxacin is used to treat complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species.
Moxifloxacin is used as a second-line agent in tuberculosis and may potentially have benefits in reducing treatment duration from its current six month to four months.
Multi-drug resistant S. pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae), and are strains resistant to 2 or more of the following antibiotics: penicillin (MIC≥2 µg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to Moxifloxacin. Molox infusion is indicated for the treatment of adult > 18 years of age.